Atavistik Bio wins FDA IND clearance and Fast Track tag for ATV-1601
Atavistik Bio has secured FDA clearance of its investigational new drug application for ATV-1601, an oral allosteric AKT1 inhibitor, alongside Fast Track Designation for the treatment of hereditary haemorrhagic telangiectasia (HHT). The Cambridge, Massachusetts-based company says the dual regulatory outcome allows it to proceed directly into a randomised proof-of-concept study, bypassing the need for a sequential dose-escalation cohort.
The cleared study, named Harmony-HHT (NCT07601425), is a Phase 1/2 design consisting of two parts. Part 1 is a randomised, double-blind, placebo-controlled, multicentre evaluation of three oral dosing regimens over 16 weeks. Eligible participants completing Part 1 may roll into an open-label extension. Atavistik Bio said it can leverage existing ATV-1601 clinical data to justify moving straight into the randomised element, a design efficiency that should compress the timeline to proof-of-concept readouts.
Disease and mechanism
HHT is caused by loss-of-function mutations in the ENG, ALK1, or SMAD4 genes, which encode proteins regulating endothelial cell growth and vessel branching. The resulting hyperactivation of the AKT1 pathway leads to arteriovenous malformations — abnormally formed blood vessels that can rupture, causing chronic bleeding, anaemia, and, in severe cases, organ damage or life-threatening haemorrhage. The condition affects more than 80,000 people in the United States and an estimated 1.6 million globally and currently has no approved pharmacological therapies. Management is largely confined to supportive care and invasive procedures such as embolisation or laser treatment.
Susan Pandya, Chief Medical Officer at Atavistik Bio, said that treatment options for patients remain "largely limited to supportive care and invasive interventions" and positioned ATV-1601 as having "the potential to provide a disease-modifying approach" for the HHT community. In preclinical models harbouring ENG, ALK1, and SMAD4 mutations, ATV-1601 reportedly reduced arteriovenous malformation formation, which the company argues supports pan-mutation applicability — a meaningful differentiator if borne out clinically, given HHT's genetic heterogeneity.
Market context and competitive landscape
The HHT space represents a narrow but underserved niche within rare vascular disease. The absence of any approved therapy means the regulatory bar for Atavistik Bio is, at minimum, a clear unmet-need argument — one the FDA has already implicitly acknowledged by granting Fast Track status, which enables more frequent agency interactions and rolling review eligibility. Fast Track does not, however, accelerate the underlying clinical timeline.
Atavistik Bio is not the only group pursuing pharmacological approaches to HHT; a small number of academic groups and companies have explored anti-angiogenic agents, including bevacizumab off-label, though none has achieved regulatory approval. An oral, once-daily disease-modifying therapy targeting the upstream AKT1 node would represent a genuinely distinct mechanism if the clinical data hold. The company is backed by The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management, suggesting it has access to sufficient capital to prosecute the Phase 1/2 programme, although no specific funding figure was disclosed in the release.
The next material milestone for investors and clinicians will be Part 1 safety and biomarker data from Harmony-HHT, likely 12 to 18 months from first patient enrolment, assuming the study opens promptly following IND clearance.